Clinical trials: Systemic Lupus
Lupus Nephritis, ANCA Associated Vasculitis
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Lupus nephritis (LN) and ANCA-associated vasculitis are severe autoimmune diseases, which may lead to the death of patients, particularly when they are refractory to the conventional therapeutic agents.
- Trial name
- NCT06277427
- Testing
- PRG-1801 （CAR-T against BCMA）
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Lingli Dong
Systemic Lupus Erythematosus
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.
- Trial name
- NCT00390091
- Testing
- abetimus sodium (LJP 394)
- Where
- 2 sites in United States
- Sponsor
- La Jolla Pharmaceutical Company
Systemic Lupus Erythematosus
IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage
Many laboratory markers can be measured for assessment of Lupus activity as aberrant manufacturing and imbalance of the cytokines of T-helper cell which already have been implicated within autoimmunity pathogenesis as IL-18 and…
- Trial name
- NCT05045417
- Testing
- Serum level of IL-17
- Where
- Egypt
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sohag University
Systemic Lupus Erythematosus
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
The purpose of this study is to assess the PK, PD, and safety of anifrolumab as SC administration or IV infusion in adult participants with systemic lupus erythematosus (SLE).
- Trial name
- NCT07688980
- Testing
- Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS
- Volunteers
- 92 people
- Sponsor
- AstraZeneca
Lupus Erythematosus, Systemic, Lupus Nephritis
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
The purpose of this study is to examine the safety of a single dose of RG2077 in patients with systemic lupus erythematosus (SLE) who are currently receiving cyclophosphamide.
- Trial name
- NCT00094380
- Testing
- CTLA4-IgG4m (RG2077), Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Erythematosus, Systemic
A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Primary objective: To assess the efficacy and safety of different dose regimens of ALX-0061 administered subcutaneously (s.c.) to subjects with moderate to severe active, seropositive systemic lupus erythematosus (SLE) compared…
- Trial name
- NCT02437890
- Testing
- ALX-0061
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 312 people
- Sponsor
- Ablynx, a Sanofi company
Lupus Nephritis, Lupus Erythematosus, Systemic
Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients
This study will collect high-quality randomized controlled data from a nationally representative sample of practicing rheumatologists to determine how they currently manage patients with SLE (systemic lupus erythematosus) and how…
- Trial name
- NCT04266860
- Testing
- Experimental - Test Results and Education
- Where
- United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Lupus Nephritis
Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla)
At this moment, the duration of the treatment in Proliferative Lupus Nephritis has not been determined. Almost 30 percent of patients in total remission during or after a treatment, will relapse in the first 5 years.
- Trial name
- LuFla (NCT02313974)
- Testing
- Renal Biopsy
- Where
- Argentina
- Volunteers
- 36 people
- Sponsor
- Hospital de Clinicas José de San Martín
Lupus Erythematosus, Systemic
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
This is an open label study to determine the association of the data obtained with LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE, including clinical involvement, SLEDAI score…
- Trial name
- ReLATE (NCT05845593)
- Testing
- Decision Support Test
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Ampel BioSolutions, LLC
Systemic Lupus Erythematosus
A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus
This is a Phase I, randomized, placebo-controlled, double-blind, dose-escalation study of single and repeat doses of rhuMAb IFNalpha, administered through the SC or IV route, in adults with Systemic Lupus Erythematosus.
- Trial name
- NCT00541749
- Testing
- rhuMAb IFNalpha
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
System; Lupus Erythematosus
Assessing the Impact of Herbal Supplement on Fatigue and Disease Activity in SLE: Results From an 8-Week Randomized Trial
Fatigue is one of the most prevalent and disabling manifestations of systemic lupus erythematosus. Although its management often entails a combination of pharmacologic and non-pharmacologic strategies, no pharmacologic…
- Trial name
- TIR-CUR (NCT07398885)
- Testing
- EVACUR
- Where
- Tunisia
- Volunteers
- 59 people
- Sponsor
- University Tunis El Manar
Systemic Lupus Erythematosus
A Study of E6742 in Participants With Systemic Lupus Erythematosus
The main purpose of the study is to demonstrate the efficacy based on dose response of E6742 compared with placebo as defined by the proportion of participants achieving a response using the British Isles Lupus Assessment Group…
- Trial name
- NCT07515014
- Testing
- E6742
- Where
- 54 sites in China, Japan and 2 more
- Volunteers
- 256 people
- Sponsor
- Eisai Co., Ltd.
Systemic Lupus Erythematosus (SLE)
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
A clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus.
- Trial name
- NCT07031713
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Autologous Stem Cell Transplantation: International Lupus Trial
The purpose of this study is to evaluate remission induction therapy for refractory Lupus Erythematosus with autologous hematopoietic stem cell transplantation (AHSCT) versus Rituximab (anti CD20) followed by maintenance therapy…
- Trial name
- ASTIL (NCT05063513)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Rituximab
- Where
- France
- Sponsor
- European Society for Blood and Marrow Transplantation
SLE, Systemic Lupus Erythematosus (SLE)
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients…
- Conditions
- SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19
- Trial name
- NCT06839976
- Testing
- CART19
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital of Philadelphia
Systemic Lupus Erythematosus, Lupus Nephritis
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- BAH242 (NCT06350110)
- Testing
- CD19- BCMA CAR-T cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
Systemic Lupus Erythematosus (SLE)
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)
- Trial name
- JY231 (NCT06675422)
- Testing
- JY231 injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
SLE - Systemic Lupus Erythematosus
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
This study is a randomized, double-blind, placebo-controlled Phase I clinical trial featuring single and multiple ascending doses.
- Trial name
- NCT07177911
- Testing
- CC312
- Where
- China
- Volunteers
- 32 people
- Sponsor
- CytoCares Inc
Systemic Lupus Erythematosus
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
- Trial name
- SunStone (NCT06559163)
- Testing
- Obexelimab
- Where
- 110 sites in United States, Belgium and 16 more
- Volunteers
- 190 people
- Sponsor
- Zenas BioPharma (USA), LLC
SLE, Atherosclerosis
Premature Atherosclerosis in Systemic Lupus Erythematosus
Patients with SLE have increased rates of atherosclerosis, while the risk factors for atherosclerosis in those patients were not fully revealed.
- Trial name
- PASLE (NCT04037293)
- Testing
- CIMT and baPWV measurement
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking Union Medical College Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.